




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61M 31/00</b>		A1	(11) International Publication Number: <b>WO 00/02616</b>
(21) International Application Number: <b>PCT/US99/14761</b>		(43) International Publication Date: <b>20 January 2000 (20.01.00)</b>	(81) Designated States: JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
(22) International Filing Date: <b>29 June 1999 (29.06.99)</b>			Published <i>With international search report.</i>
(30) Priority Data: 09/112,102 8 July 1998 (08.07.98) US			
(71) Applicant: INNERDYNE, INC. [US/US]; 1244 Reamwood Avenue, Sunnyvale, CA 94089 (US).			
(72) Inventors: ORTH, Michael, J.; 15875 Walter Breton Drive, Morgan Hill, CA 95037 (US). YANG, Mark, C.; 255 Mountain View Avenue, Mountain View, CA 94041-1111 (US).			
(74) Agents: HESLIN, James, M. et al.; Townsend and Townsend and Crew LLP, 8th floor, Two Embarcadero Center, San Francisco, CA 94111 (US).			

(54) Title: METHODS, SYSTEMS, AND KITS FOR IMPLANTING ARTICLES

## (57) Abstract

This invention is methods, systems (10, 12), and kits for subcutaneously implanting articles such as drug inserts, and reservoirs.



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

5

## METHODS, SYSTEMS, AND KITS FOR IMPLANTING ARTICLES

### BACKGROUND OF THE INVENTION

#### 10 1. Field of the Invention

The present invention relates generally to medical methods, apparatus, and kits. More particularly, the present invention relates to methods, systems, and kits for percutaneously delivering implantable articles, such as 15 subcutaneous drug inserts, to solid tissue locations.

Implantable articles are useful for a wide variety of medical purposes. Of particular interest to the present invention, drug inserts and controlled release reservoirs may be subcutaneously implanted in order to release a drug or 20 other biologically active substance over time. Usually, the insert or reservoir will be implanted intramuscularly or intraperitoneally by first forming an incision which permits the article to be implanted at the target site. Often, a large bore needle or cannula is used to inject the insert or 25 reservoir to the target location. Such devices, however, often result in coring of the tissue, and subsequent injection of the drug insert pushes against such cored tissue, rendering placement difficult. While such problems have been at least partly overcome by the use of trocar/cannula assemblies where 30 the trocar cuts through tissue, the use of relatively large diameter trocars is traumatic to the patient and can leave scarring.

An improvement over the use of large diameter needles and trocars is proposed in U.S. Patent No. 5,304,119.

35 The '119 patent teaches use of a tapered cannula having a pair of opposed tines over its distal end. The tines meet together in a "duck bill" fashion and may be advanced through solid tissue with reduced trauma to the patient. After initial placement of the cannula, a drug insert may be 40 advanced axially through the device, forcing the opposed tines

to open and permitting placement of the insert at the desired target location. While workable and an improvement over prior delivery systems, reliance on passage of the drug insert to open the opposed tines can be problematic. In particular, the 5 mechanical action can physically damage the drug insert prior to its delivery to the tissue target site.

For these reasons, it would be desirable to provide improved methods, systems, and kits for delivering implantable articles, such as drug inserts and controlled release 10 reservoirs, to solid tissue locations. In particular, it would be desirable to provide for percutaneous delivery of such articles in a manner which is both minimally traumatic to the patient and minimally damaging to the article. At least some these objectives will be met by the invention described 15 hereinafter.

## 2. Description of the Background Art

A device and method for injecting implants are described in U.S. Patent No. 5,304,119, discussed in more 20 detail above. Radially expanding dilators of a type suitable for use in the methods of the present invention are described in U.S. Patent Nos. 5,183,464 and 5,431,676, and are commercially available under the tradename STEP™ from 25 InnerDyne, Inc., Sunnyvale, California, assignee of the present application. Other pertinent patents include U.S. Patent Nos. 5,674,240; 5,484,403; 5,403,278; 5,201,756; 4,899,729; 4,716,901; and 3,788,318.

## SUMMARY OF THE INVENTION

30 According to the present invention, improved methods, systems, and kits are provided for implanting articles in solid tissue. The articles will usually be intended for drug delivery, typically being drug delivery inserts or reservoirs intended for controlled release of the 35 drugs, but could also be intended for other purposes such as the delivery of brachytherapy seeds, pacemakers and other stimulatory devices and leads, pumps, transducers and other diagnostic and monitoring devices, sensors, and the like. The

methods and systems of the present invention are characterized by the formation and radial expansion of a tissue tract from the surface of a patient's skin to a target site beneath the skin, typically within solid tissue (e.g., muscle), beneath the peritoneum, (i.e., the retroperitoneum), or the like. The tissue tract is radially expanded, preferably, to a substantially constant lumen diameter over its entire length, with the expansion occurring prior to introduction of the drug insert or other article. Radial expansion of the tissue tract is generally less traumatic to the patient than use of a large bore coring needle or large diameter trocar, and full expansion of the tissue tract prior to introduction of the article avoids the risk of damage to the article which can occur with systems such as that described in U.S. Patent No. 5,304,119, where the article itself mechanically opens a path as it is advanced.

In a first aspect, a method according to the present invention comprises percutaneously inserting a radially expandable sleeve so that a distal end of the sleeve lies adjacent to a target site in solid tissue. An assembly comprising a cannula and a dilator is then introduced through the radially expandable sleeve, where the cannula and dilator have a diameter which is larger than an initial diameter of the sleeve so that the sleeve is radially expanded as the assembly is advanced distally through a lumen of the sleeve. Usually, the dilator will have a tapered or pointed distal end which facilitates advancement through the sleeve and which can extend beyond the distal end of the sleeve to penetrate the solid tissue and create a potential space for receiving the article to be implanted.

After the cannula/dilator assembly has been fully advanced within the sleeve, the dilator is removed from the cannula, leaving the cannula in place to maintain an open lumen having a diameter which is significantly greater than the initial lumen diameter of the sleeve. Usually, the luminal diameter of the cannula will be in the range from 2 mm to 20 mm, preferably from 3 mm to 12 mm, most typically from 3 mm to 5 mm, while the initial lumen diameter of the sleeve

will be less than 1 mm. After the dilator has been removed from the cannula, the article is advanced distally through the cannula lumen and beyond the distal end of the cannula so that it enters into the tissue where it is to be implanted.

5 Conveniently, the article can be advanced using the same dilator which was originally used to advance the assembly of the cannula and dilator. Alternatively, a separate pusher rod or other element may be provided for insertion, advancement, and implantation of the article.

10 Usually, the percutaneous sleeve inserting step will comprise advancing an assembly of the sleeve and a needle directly into the tissue. The needle will usually be a small diameter, non-coring needle having a sharpened distal tip which extends distally of the sleeve to facilitate advancement 15 of the assembly through the tissue. The needle may then be withdrawn proximally from the sleeve, leaving the sleeve in place to receive introduction of the assembly of the cannula and dilator in a subsequent step. In the exemplary embodiment, the expandable sleeve comprises a tubular braid 20 formed from a mesh of non-elastic filaments which axially shorten as they are radially expanded.

The article will preferably be a drug delivery implant or controlled and sustained release reservoir. The article may be used for delivering a wide variety of drugs of 25 the type which are suitable for subcutaneous intramuscular implantation, such as contraceptives, hormonal replacement, e.g. estrogen, progesterone, testostoronen, and the like.

In a second aspect, the method of the present invention comprises radially expanding a tissue tract to form 30 a lumen having a substantially constant diameter over its entire length. The article to be implanted is then advanced distally through the lumen after the lumen has been substantially completely expanded. In this way, patient trauma is reduced while the risk of damage to the implanted 35 article is minimized.

The present invention further comprises kits including a radially expandable sleeve, a cannula, and a dilator. The kit will further comprise instructions for use

setting forth any of the methods described above. The kit usually will further comprise a container for holding the various kit components together, typically being a pouch, tray, box, tube, or the like. The kit components will usually 5 be sterilized and maintained steriley within the packaging, where sterilization can be effected by conventional means, such as radiation, exposure to ethyleneoxide, or the like. Optionally, the kit may further comprise the article to be 10 implanted, typically being a pharmaceutical implant or reservoir.

The present invention still further comprises systems including both a radially expandable sleeve and a drug delivery article. The radially expandable sleeve will be expandable from a narrow diameter configuration which can be 15 percutaneously introduced to the patient with lessened patient trauma and which will be radially expandable to a large diameter configuration in order to provide a non-collapsible lumen. The drug delivery article will have peripheral dimensions which permit it to be delivered through the non- 20 collapsible lumen of the sleeve after radial expansion. The lumen of the sleeve will be capable of remaining fully open to its large diameter configuration even in the absence of the article so that the article may be passed through the lumen without the need for the article to help open the lumen. 25 Usually, the radially expandable sleeve will be opened using an assembly of a cannula and a dilator as generally described above.

#### BRIEF DESCRIPTION OF THE DRAWINGS

30 Fig. 1 illustrates a radially expandable sleeve and a needle having a sharpened distal tip which may be received in a lumen of the sleeve to be used in the methods of the present invention.

35 Fig. 2 illustrates a dilator and cannula which may be formed into an assembly and used in the methods of the present invention.

Figs. 3-10 illustrate the method of the present invention for subcutaneously implanting an article.

Fig. 11 illustrates a kit constructed in accordance with the principles of the present invention.

#### DESCRIPTION OF THE SPECIFIC EMBODIMENTS

Referring to Fig. 1, a radially expandable sleeve 10 and needle 12 which may be used in the methods and systems of the present invention are illustrated. The sleeve 10 comprises a tubular sheath 14 having a proximal end 16 and a distal end 18. The proximal end 16 is tapered radially outward in the proximal direction and secured to a handle 20.

An aperture (not shown) in the handle is aligned with the expanded diameter of the proximal end 16 and includes a bayonet fitting 22 aligned with the aperture. The tubular sheath 14 may comprise any material which is capable of receiving the assembly of the cannula and dilator to effect radial expansion of the sheath, as described in more detail hereinafter. In the exemplary embodiment, the sheath comprises an inelastic braid covered by an elastic membrane, as generally described in U.S. Patent No. 5,431,676, the full disclosure of which is incorporated herein by reference. Suitable expandable sleeves 10 may be obtained commercially from InnerDyne, Inc., Sunnyvale, California, as part of the STEP™ system.

The needle 12 may comprise a simple solid core rod 24 having a sharpened distal tip 26. Alternatively, the needle may be cannulated to confirm placement by aspiration or drop tests and/or to facilitate over-the-wire placement. The diameter of the needle will typically be in the range from 1 mm to 2 mm, and advancement of the needle through tissue will generally not result in coring of the tissue. When the needle 12 is placed in the lumen of sleeve 10, the sharpened tip 26 will extend out of the distal end of the sleeve, typically by distance in the range from 1 mm to 3 mm.

The methods and the systems of the present invention will further utilize an assembly of a cannula 30 and dilator 40, as illustrated in Fig. 2. The cannula 30 comprises a rigid, thin-walled tubular member 32 having a distal end 34 and a proximal end 36. A handle 38 having an aperture aligned

with a lumen of the tubular member 32 is attached to the proximal end of the tubular member. The dilator 40 comprises a solid core shaft 42 having a tapered distal end 44 and a handle 46 at its proximal end. The dilator may be removably inserted into the lumen of cannula 30 so that the tapered distal end of the dilator extends distally beyond distal end 34 of the cannula. The luminal diameter of the cannula will typically be within the ranges set forth above.

Referring now to Figs. 3-10, a method according to the present invention for delivering a drug insert 60 (Fig. 7) will be described. Initially, the assembly of sleeve 10 and needle 12 will be percutaneously introduced to a target site TS beneath the patient's skin S (Fig. 3). After reaching the target site TS, the needle 12 is withdrawn in the proximal direction, as shown by arrow 62 in Fig. 4. After fully withdrawing the needle 12, the assembly of cannula 30 and dilator 40 may be introduced through the inner lumen of the expandable sleeve 10, as shown in Fig. 5. The tapered end 44 of the dilator 40 will extend into the tissue at the target site TS. The dilator 40 may then be withdrawn in the proximal direction, indicated by arrow 64 in Fig. 6, leaving the cannula 30 in place within the radially expanded sleeve 10. An opening or potential space O is thus created at the distal end 34 of the cannula 30 after the dilator 40 is withdrawn. The length of the opening will depend on the distance by which the dilator 40 has advanced into the tissue, typically being from 1 mm to 30 mm, usually from 5 mm to 15 mm, depending on the size of the article to be delivered. Alternatively, the opening O could be formed by partially withdrawing the distal end of the cannula 30 prior to insertion of the article to be implanted. The drug insert 60 or other article may then be introduced distally through the lumen of the cannula 30 in the direction of arrow 66, as shown in Fig. 7. Conveniently, the dilator 40 may be used to push the insert 60 so that it extends into the potential space O, as also shown in Fig. 8.

After the insert 60 is fully implanted, as shown in Fig. 8, the dilator 40 may be withdrawn, followed by withdrawal of the cannula 30 in the direction of arrow 70, as

shown in Fig. 9. As the cannula 30 is proximally withdrawn, the sleeve 10 will collapse, allowing the sleeve 10 to be readily withdrawn in the direction of arrow 72, as shown in Fig. 10. Collapse of the sleeve lessens trauma to the 5 patient.

Kits according to the present invention will comprise at least some of the components thereof packaged together with instructions for use 80, as shown in Fig. 11. For example, the assembly of radially expandable sleeve 10 and 10 needle 12 may be packaged together with the assembly of cannula 30 and dilator 40 in a pouch 82, or other conventional container, such as tray, tube, box, or the like. The instructions for use 80 will set forth any of the methods described above for percutaneously introducing an article 15 beneath a patient's skin for subcutaneous implantation.

While the above is a complete description of the preferred embodiments of the invention, various alternatives, modifications, and equivalents may be used. Therefore, the above description should not be taken as limiting the scope of 20 the invention which is defined by the appended claims.

WHAT IS CLAIMED IS:

1           1. A method for implanting an article in solid  
2 tissue, said method comprising:

3               percutaneously inserting a radially expandable  
4 sleeve so that a distal end thereof lies adjacent to a target  
5 site in solid tissue;

6               introducing an assembly of a cannula and dilator  
7 through the radially expandable sleeve, wherein the diameter  
8 of the sleeve is expanded;

9               removing the dilator from the cannula to leave an  
10 open lumen to the tissue target site; and

11               advancing the article through the cannula lumen and  
12 into the tissue target site.

1           2. A method as in claim 1, wherein the sleeve  
2 inserting step comprises advancing an assembly of the sleeve  
3 and a needle into the tissue, wherein a sharpened distal tip  
4 of the needle is disposed distally of the sleeve to advance  
5 through the tissue first.

1           3. A method as in claim 1, wherein the expandable  
2 sleeve comprises a tubular braid formed of a mesh of non-  
3 elastic filaments which axially shorten as they are expanded.

1           4. A method as in claim 1, wherein the assembly  
2 introducing step comprises penetrating a tapered distal end of  
3 the dilator into the tissue disposed distally of the distal  
4 end of the sleeve in order to create an opening in the solid  
5 tissue to receive the article.

1           5. A method as in claim 1, wherein the cannula  
2 lumen has a diameter in the range from 2 mm to 20 mm.

1           6. A method as in claim 1, wherein the inserting  
2 step comprises introducing the sleeve intramuscularly or  
3 subcutaneously.

1           7. A method as in claim 6, wherein the article is  
2 an implant which releases a drug selected from the group  
3 consisting of estrogen, progesterone, and testosterone.

1           8. An improved method for implanting an article  
2 into solid tissue, said method being of the type wherein a  
3 tissue tract is formed and dilated to permit advancement of  
4 the article, wherein the improvement comprises:

5           radially expanding the tissue tract to form a lumen  
6 having a substantially constant diameter; and  
7           advancing the article through the lumen after the  
8 lumen has been substantially completely expanded.

1           9. An improved method as in claim 8, wherein the  
2 radial expanding step comprises:

3           percutaneously inserting a radially expandable  
4 sleeve so that a distal end thereof lies adjacent to a target  
5 site in solid tissue;

6           introducing an assembly of a cannula and dilator  
7 through the radially expandable sleeve, wherein the sleeve is  
8 radially expanded; and

9           removing the dilator from the cannula to leave the  
10 substantially constant diameter lumen to the target site.

1           10. A method as in claim 9, wherein the sleeve  
2 inserting step comprises advancing an assembly of the sleeve  
3 and a needle into the tissue, wherein a sharpened distal tip  
4 of the needle is disposed distally of the sleeve to advance  
5 through the tissue first.

1           11. A method as in claim 9, wherein the expandable  
2 sleeve comprises a tubular braid formed of a mesh of non-  
3 elastic filaments which axially shorten as they are expanded.

1           12. A method as in claim 9, wherein the assembly  
2 introducing step comprises penetrating a tapered distal end of  
3 the dilator into the tissue disposed distally of the distal  
4 end of the sleeve in order to create an opening in the solid

5 tissue to receive the article.

1 13. A method as in claim 9, wherein the cannula  
2 lumen has a diameter in the range from 2 mm to 20 mm.

1 14. A method as in claim 9, wherein the inserting  
2 step comprises introducing the sleeve intramuscularly or  
3 subcutaneously.

1 15. A method as in claim 14, wherein the article is  
2 an implant which releases a drug selected from the group  
3 consisting of estrogen, progesterone, and testosterone.

1 16. A kit comprising:  
2 a radially expandable sleeve;  
3 a cannula;  
4 a dilator; and  
5 instructions for use according to the method of  
6 claim 1.

1 17. A kit as in claim 16, further comprising an  
2 article to be implanted.

1 18. A kit as in claim 17, wherein the article  
2 comprises a pharmaceutical implant.

1 19. A system for implanting a drug delivery article  
2 in a patient, said system comprising:  
3 a radially expandable sleeve, said sleeve being  
4 expandable from a narrow diameter configuration to a large  
5 diameter configuration and providing a non-collapsible lumen;  
6 and

7 a drug delivery article having peripheral dimensions  
8 which permit it to be delivered through the non-collapsible  
9 lumen, wherein the lumen can remain fully open to its large  
10 diameter configuration in the absence of the article therein.

1 20. A system as in claim 19, further comprising an

2 assembly of a cannula and a dilator removably received in a  
3 lumen of the cannula, wherein the assembly is configured to be  
4 advanced through the sleeve to radially expand the sleeve and  
5 wherein the dilator can be removed from the cannula to leave  
6 the non-collapsible lumen through the sleeve.

1/7




FIG. 1.

SUBSTITUTE SHEET (RULE 26)




FIG. 2.

SUBSTITUTE SHEET (RULE 26)

3/7




FIG. 3.




FIG. 4.

4/7




FIG. 5.




FIG. 6.

5/7




FIG. 7.




FIG. 8.

6/7




FIG. 9.




FIG. 10.

7/7




FIG. 11.

SUBSTITUTE SHEET (RULE 26)

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/14761

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61M 31/00

US CL :604/49

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 604/49, 57, 104, 164, 171, 500, 502, 506

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,183,464 A (DUBRUL et al) 02 February 1993, cols. 1-11.	1, 2, 4-6, 8-10, 12-14, 16, 17, 19, 20
---		
Y		3, 7, 11, 15, 18

Further documents are listed in the continuation of Box C.  See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance		
"E" earlier document published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed	"&"	document member of the same patent family

Date of the actual completion of the international search

20 AUGUST 1999

Date of mailing of the international search report

07 OCT 1999

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer  
KENT GRING  
Telephone No. (703) 308-2214